

Key Investor Information

This document provides you with key investor information about this Compartment. It is not marketing material. The information is required by law to help you understand the nature and the risks of investing in this Compartment. You are advised to read it so you can make an informed decision about whether to invest.

CPR Invest - MedTech - F EUR - Acc A Compartment of CPR Invest (SICAV)

ISIN code : (A) LU2036817984

This Compartment is managed by CPR Asset Management, a company of the group Amundi

Objectives and Investment Policy

The investment objective is to outperform global equity markets over a long-term period (minimum of five years) by investing in international equities of companies involved in the medical technology ecosystem, while integrating Environmental, Social and Governance (E, S, and G - or, when taken together, ESG) criteria in the investment process.

To achieve this, the Compartment aims to select equities of companies with the best financial perspectives within a universe of companies involved in the medical technology ecosystem through sector such as diagnostics, surgery, medical monitoring, disease prevention, treatment.

The Management Company integrates a sustainable approach by excluding companies based on the following:

- worst overall ESG ratings;
- worst ratings on E, S and G specific criteria deemed relevant for the medical technology ecosystem;
- high ESG controversies;

The Compartment equity exposure will be between 75% and 120% of its assets.

The Compartment is invested for at least 75% of its assets in equity and equity equivalent securities of any country without constraints of capitalisation. Among this proportion of 75% of its assets, the Compartment may invest in China A shares via Stock Connect within a maximum of 25% of its assets.

Derivatives instruments will be used by the Compartment for hedging, arbitrage, exposure purposes and/or efficient portfolio management.

The Compartment is actively managed. The Compartment may use a Benchmark a posteriori as an indicator for assessing the Compartment's performance and, as regards the performance fee benchmark used by relevant share classes, for calculating the performance fees. There are no constraints relative to any such Benchmark restraining portfolio construction.

The Compartment is a financial product that promotes ESG characteristics pursuant to Article 8 of the Disclosure Regulation.


CPR Invest - MedTech - F EUR - Acc is EUR denominated.

CPR Invest - MedTech - F EUR - Acc has a recommended investment horizon of more than 5 years.

CPR Invest - MedTech - F EUR - Acc accumulates its net profit and net realized capital gains.

You may redeem your shares at each net asset value, calculated on a daily basis in accordance with the terms specified in the prospectus.

Risk and Reward Profile



This Compartment's risk level reflects its international equities investment theme.

- The historical data used to calculate the numeric risk indicator could not be a reliable indicator of the future risk profile of the Compartment.
- The risk category associated with this Compartment is not guaranteed and may shift over time.
- The lowest category does not mean 'risk free'.
- The capital is not guaranteed.

Major risks for the Compartment not included in the indicator are :

- Credit risk: this is the risk of sudden downgrading in the creditworthiness of an issuer or that of its default.
- Liquidity risk: it presents the risks that a financial market, when volumes traded are low or if there are tensions on such market, might not be able to absorb the sell (or buy) volumes without causing the price of the assets to significantly drop (or rise).
- Counterparty risk: this is the risk of default of a market participant preventing it from honoring its commitments in respect of your portfolio.
- The use of financial derivatives instruments might increase or decrease the capacity of your portfolio to amplify market's movements.

The occurrence of any of these risks may lower the net asset value of your Compartment. To learn more about the risks, please refer to the Risk Profile section of the Compartment in the prospectus.

Charges

The charges you pay are used to pay the costs of running the Compartment, including the costs of marketing and distributing it. These charges reduce the potential growth of your investment.

One-off charges taken before or after you invest

Entry charge None

Exit charge None

The percentage indicated is the maximum that might be taken from your capital before it is invested (entry) or redeemed (exit).

Charges taken from the Compartment over a year

Ongoing charges 2,69%* (including tax) of the average net assets

Charges taken from the Compartment under certain specific conditions

Performance fee 15% (including tax) annual of the performance of the Compartment above the Reference Asset.

The Performance observation period, which started from the launch of the share, is exceptionally extended until the last net asset value per Share of July 2022.

No commission was taken over the last accounting year.

The **entry and exit charges** shown are maximum figures. In some cases you might pay less - you can find this out from your financial adviser.

*The ongoing charges figure is based on expenses for the year ending December 31, 2021. This figure may vary from year to year.

It excludes :

- Performance fees,
- Portfolio transaction costs, except in the case of an entry/exit charge paid by the Compartment when buying or selling units or shares in another UCI.

The calculation of the performance fee applies on each net asset value calculation date in accordance with the terms and conditions described in the prospectus.

The comparison of the net assets of the share and the Reference Asset (as defined in the prospectus) is carried out over an observation period of maximum five years. The performance fee represents 15% of the difference between the net asset of the share (before deduction of the performance fee) and the Reference Asset if the difference is positive, and if the relative performance of the share class compared to the Reference Asset is positive or nil, since the beginning of the performance observation period. Past underperformances over the last 5 years should be clawed back before any new accrual of performance fee.

The anniversary date corresponds to the day of calculation of the last net asset value of the month of July.

Performance fee accruals will be paid to the Management Company on an anniversary date and a new observation period starts.

The performance fee is paid even if the performance of the share over the performance observation period is negative, while remaining higher than the performance of the Reference Asset.

For more information about charges of the Compartment, please refer to the "Charges and expenses" section of the prospectus, which is available at www.cpr-am.com or upon request from the Management Company.

Past Performance

CPR Invest - MedTech - F EUR - Acc does not yet have the full calendar year data needed to generate a performance chart.

- The Compartment was approved on October 23, 2019.
- The Compartment was launched on December 12, 2019.
- The Share Class was launched on December 12, 2019.
- This Compartment does not have a benchmark index.
The MSCI World Health Care Equipment and Supplies 10/40 Index NR denominated in the currency of the Share Class (EUR) is for performance comparison purposes and if applicable, for calculating the performance fees.
- Annual performance is calculated on the basis of the net asset values denominated in EUR and all fees included.

Practical Information

www.CPR-AM.com

- Name of the depositary : CACEIS Bank, Luxembourg Branch.
- Where and how to obtain information about the Compartment (prospectus, annual report, half-yearly document) and/or the other categories of shares : this information is available in English, free of charge and upon written request to CPR Asset Management – 91-93, boulevard Pasteur 75015 Paris - France or at www.cpr-am.com.
- The UCITS contains a large number of other Compartments and other share classes which are described in the prospectus. Conversion into shares of another Compartment of the UCITS may be made, subject to the conditions of the prospectus.
- Each Compartment corresponds to a distinct part of the assets and liabilities of the UCITS. As a consequence, the assets of each Compartment are exclusively available to satisfy the rights of investors in relation to that Compartment and the right of creditors whose claims have arisen in connection with the creation, the operation or the liquidation of that Compartment.
- This document describes a Compartment of the UCITS. The prospectus and periodical reports are prepared for the entire UCITS named at the beginning of this document.
- Depending upon your personal tax position, capital gains and any income associated with holding securities in the Compartment may be subject to taxation. We advise you to seek information about this from the UCITS' distributor.
- The Compartment's net asset value is available at each calculation from the Management Company.
- The Compartment is not open to residents of the United States of America/to « U.S. Persons » as defined in the legal notice of the Management Company website: www.cpr-am.com and/or in the UCITS' prospectus.

The details of the up-to-date remuneration policy of the Management Company, including, but not limited to, a description of how remuneration and benefits are calculated, the identity of persons responsible for awarding the remuneration and benefits are available by means of the following website: www.cpr-am.com, and a paper copy will be made available free of charge upon request. CPR Asset Management may be held liable solely on the basis of any statement contained in this document that is misleading, inaccurate or inconsistent with the relevant parts of the UCITS' prospectus.

This Compartment is authorised in Luxembourg and supervised by the Commission de Surveillance du Secteur Financier (CSSF).

CPR Asset Management is authorised in France and regulated by the Autorité des Marchés Financiers (AMF).

This key investor information is accurate as at April the 29th, 2022.